RU95108244A - Производные арилиден- и гетероарилиденоксиндола и способ их получения, лекарственный препарат на их основе и способ его получения - Google Patents

Производные арилиден- и гетероарилиденоксиндола и способ их получения, лекарственный препарат на их основе и способ его получения

Info

Publication number
RU95108244A
RU95108244A RU95108244/04A RU95108244A RU95108244A RU 95108244 A RU95108244 A RU 95108244A RU 95108244/04 A RU95108244/04 A RU 95108244/04A RU 95108244 A RU95108244 A RU 95108244A RU 95108244 A RU95108244 A RU 95108244A
Authority
RU
Russia
Prior art keywords
alkyl
preparation
independently hydrogen
derivatives
hydrogen
Prior art date
Application number
RU95108244/04A
Other languages
English (en)
Inventor
Буззетти Франко
It]
Лонго Антонио
Габриэлла Браска Мария
Орзи Фабрицио
Кругнола Анджело
Баллинари Дарио
Мариани Марианджела
Original Assignee
Фармация С.п.А. (IT)
Фармация С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация С.п.А. (IT), Фармация С.п.А. filed Critical Фармация С.п.А. (IT)
Publication of RU95108244A publication Critical patent/RU95108244A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/36—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Предложены производные арилиден- и гетероарилиденоксиндола формулы Iв которой Y - бициклическое кольцо, выбранное из нафталина, тетралина, хинолина и изохинолина; R - водород или оксо (=O) группа, когда Y - нафталин, хинолин, или изохинолин; каждый из Rи Rнезависимо - водород, C-C-алкил или C-C-алканоил; m - 0, 1 или 2; n - 0, 1, 2 или 3; каждый из Rи Rнезависимо - водород, галоген, циано, C-C-алкил, карбокси, нитро или -NRR, в котором каждый из Rи Rнезависимо - водород или C-C-алкил, и их фармацевтически приемлемые соли, которые являются пригодными в качестве ингибиторов тирозинкиназы. Предложены также способ их получения и лекарственные препараты используемые в противораковой терапии. Кроме того предложен способ получения лекарственного препарата путем смешения активного компонента и фармацевтически приемлемых носителей и/или разбавителей.

Claims (1)

  1. Предложены производные арилиден- и гетероарилиденоксиндола формулы I
    Figure 00000001

    в которой Y - бициклическое кольцо, выбранное из нафталина, тетралина, хинолина и изохинолина; R - водород или оксо (=O) группа, когда Y - нафталин, хинолин, или изохинолин; каждый из R1 и R2 независимо - водород, C1-C6-алкил или C1-C6-алканоил; m - 0, 1 или 2; n - 0, 1, 2 или 3; каждый из R3 и R4 независимо - водород, галоген, циано, C1-C6-алкил, карбокси, нитро или -NR6R7, в котором каждый из R6 и R7 независимо - водород или C1-C6-алкил, и их фармацевтически приемлемые соли, которые являются пригодными в качестве ингибиторов тирозинкиназы. Предложены также способ их получения и лекарственные препараты используемые в противораковой терапии. Кроме того предложен способ получения лекарственного препарата путем смешения активного компонента и фармацевтически приемлемых носителей и/или разбавителей.
RU95108244/04A 1993-07-01 1994-05-26 Производные арилиден- и гетероарилиденоксиндола и способ их получения, лекарственный препарат на их основе и способ его получения RU95108244A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9313638.0 1993-07-01
GB939313638A GB9313638D0 (en) 1993-07-01 1993-07-01 Arylidene and heteroarylidene oxindole derivatives and process for their preparation

Publications (1)

Publication Number Publication Date
RU95108244A true RU95108244A (ru) 1997-03-20

Family

ID=10738142

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95108244/04A RU95108244A (ru) 1993-07-01 1994-05-26 Производные арилиден- и гетероарилиденоксиндола и способ их получения, лекарственный препарат на их основе и способ его получения

Country Status (23)

Country Link
US (1) US5656654A (ru)
EP (2) EP0987263B1 (ru)
JP (1) JP3737826B2 (ru)
KR (1) KR950702979A (ru)
CN (1) CN1111454A (ru)
AT (2) ATE360013T1 (ru)
AU (1) AU679754B2 (ru)
CA (1) CA2142472A1 (ru)
DE (2) DE69434955T2 (ru)
DK (1) DK0658159T3 (ru)
ES (2) ES2300132T3 (ru)
FI (1) FI950859A0 (ru)
GB (1) GB9313638D0 (ru)
GR (1) GR3034854T3 (ru)
HU (1) HUT72047A (ru)
IL (1) IL110131A0 (ru)
MX (1) MX9404885A (ru)
NZ (1) NZ267423A (ru)
PL (1) PL307741A1 (ru)
PT (1) PT658159E (ru)
RU (1) RU95108244A (ru)
WO (1) WO1995001349A1 (ru)
ZA (1) ZA944730B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
HUP9800757A3 (en) * 1996-01-17 1998-08-28 Taiho Pharmaceutical Co Ltd Intimal thickening inhibitors containing oxyindole derivatives and pharmaceutical compositions containing them
GB9610964D0 (en) * 1996-05-24 1996-07-31 Pharmacia & Upjohn Spa Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9611797D0 (en) * 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
EP1247803A3 (en) * 1996-08-23 2002-10-16 Sugen, Inc. Indolinone compounds suitable for modulation of protein kinases
US5917028A (en) * 1996-10-29 1999-06-29 Incyte Pharmaceuticals, Inc. Human phosphoprotein
AU7622698A (en) * 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
US6051593A (en) 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
JP2002504529A (ja) 1998-02-27 2002-02-12 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 二置換ラベンダスティンａ類似体およびこれらの類似体を含む薬学的組成物
US6043254A (en) * 1998-04-03 2000-03-28 Boehringer Ingelheim Pharma Kg Indolinones having kinase-inhibiting activity
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6525072B1 (en) * 1998-08-31 2003-02-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
JP2002532492A (ja) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
CN1158283C (zh) 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
EP1165513A1 (en) * 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
EP1259234B9 (en) * 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6504034B2 (en) 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
BR0306785A (pt) * 2002-01-07 2004-11-09 Eisai Co Ltd Deazapurinas e seus usos
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
CN102115469A (zh) * 2011-03-21 2011-07-06 浙江大学 吲哚啉-2-酮类衍生物的制备和用途
US9296730B2 (en) 2012-10-26 2016-03-29 Regents Of The University Of Minnesota Aurora kinase inhibitors
US10487054B2 (en) 2017-04-21 2019-11-26 Regents Of The University Of Minnesota Therapeutic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
GB9000939D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa Improvement in the total synthesis of erbstatin analogs
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
EP0549348A1 (en) * 1991-12-24 1993-06-30 PHARMACIA S.p.A. Arylidene-heterocyclic derivatives, process for their preparation and their use as tyrisine kinase inhibitors

Also Published As

Publication number Publication date
DE69425637D1 (de) 2000-09-28
DK0658159T3 (da) 2000-12-18
ES2152317T3 (es) 2001-02-01
ATE360013T1 (de) 2007-05-15
PL307741A1 (en) 1995-06-12
CA2142472A1 (en) 1995-01-12
KR950702979A (ko) 1995-08-23
IL110131A0 (en) 1994-10-07
FI950859A (fi) 1995-02-24
ZA944730B (en) 1995-07-13
AU679754B2 (en) 1997-07-10
JPH08500847A (ja) 1996-01-30
ES2300132T3 (es) 2008-06-01
HU9500954D0 (en) 1995-05-29
AU6971994A (en) 1995-01-24
DE69434955D1 (de) 2007-05-31
DE69434955T2 (de) 2008-01-17
PT658159E (pt) 2001-01-31
DE69425637T2 (de) 2001-05-03
ATE195734T1 (de) 2000-09-15
MX9404885A (es) 1995-01-31
WO1995001349A1 (en) 1995-01-12
NZ267423A (en) 1996-03-26
JP3737826B2 (ja) 2006-01-25
EP0987263A2 (en) 2000-03-22
GB9313638D0 (en) 1993-08-18
FI950859A0 (fi) 1995-02-24
EP0658159B1 (en) 2000-08-23
EP0987263B1 (en) 2007-04-18
HUT72047A (en) 1996-03-28
EP0658159A1 (en) 1995-06-21
EP0987263A3 (en) 2003-10-15
GR3034854T3 (en) 2001-02-28
CN1111454A (zh) 1995-11-08
US5656654A (en) 1997-08-12

Similar Documents

Publication Publication Date Title
RU95108244A (ru) Производные арилиден- и гетероарилиденоксиндола и способ их получения, лекарственный препарат на их основе и способ его получения
JP6716785B2 (ja) Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
Yeung et al. Spirotetrahydro β-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria
RU96105827A (ru) Пиридо[3,2-е]пиразиноны, способы их получения и применение, лекарственный препарат и способ его получения
RU94031208A (ru) Фармацевтическая композиция, связанное циклическое соединение и способ его получения
JP2010215656A (ja) エクテイナシジン７４３の代謝産物
HUP0105231A2 (hu) Heteroaril-szubsztituált kinolin-2-on-származék rákellenes szerek és a vegyületeket tartalmazó gyógyszerkészítmények
RU96112103A (ru) Новые бензоилгуанидины, их получение и применение в лекарственных средствах
JP2023533915A (ja) Ｈｉｖの治療のためのカプシド阻害剤
JP2007509057A (ja) ウイルス阻害のための組成物および方法
BR112021006033A2 (pt) Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina
SE8302361D0 (sv) New tricyclic amines
KR960702442A (ko) 타이로신 키나아제 억제인자로서의 치환된 β-아릴 및 β-헤테로아릴-α-시아노아크릴아미드 유도체(Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors)
RU2001121160A (ru) Применение производных пиридазино[4,5-b]индол-1-ацетамида для приготовления лекарств для лечения заболеваний, связанных с дисфункцией бензодиазепиновых рецепторов периферического типа
JP2006517949A5 (ru)
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
CA2539549A1 (en) Pyrazolopyrrole derivatives as protein kinase inhibitors
JP2010510216A5 (ru)
CN1299358A (zh) 杂环拓扑异构酶毒性剂
AU618991B2 (en) Indoloquinoline system compounds, process for their preparation, and carcinostative composition containing them
CN110229159B (zh) 卢索替尼的氘代衍生物
Nicely et al. One-pot two-step catalytic synthesis of 6-amino-2-pyridone-3, 5-dicarbonitriles enabling anti-cancer bioactivity
CN87106996A (zh) 喹啉基化合物，它们的制备方法和以其作为有效药物组分的抗癌剂
JP2020503376A5 (ru)
CN103896918A (zh) 化合物及其制备方法和用途